Molecular genetics in myelodysplastic syndromes

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic syndromes (MDS) diagnosis traditionally relies on cytomorphology and cytogenetics.
• Fluorescence in situ hybridisation (FISH) and immunophenotyping offer additional diagnostic insights.
• Current prognostication uses the International Prognostic Scoring System (IPSS) or its revised version, incorporating cytopenias, morphology, and cytogenetics.

Purpose of the Study:

• To review current diagnostic and prognostic methods for myelodysplastic syndromes (MDS).
• To highlight the emerging role of molecular markers and next-generation sequencing in MDS.
• To anticipate future directions in MDS management incorporating genetic findings.

Main Methods:

• Review of cytomorphology and cytogenetics in MDS diagnosis.
• Application of fluorescence in situ hybridisation (FISH) and immunophenotyping.
• Analysis of molecular markers, including next-generation sequencing (NGS) and whole exome sequencing (WES).

Main Results:

• Diagnosis of MDS remains dependent on peripheral blood and bone marrow smear morphology.
• Cytogenetics, FISH, and immunophenotyping provide crucial data for diagnosis and prognosis.
• Molecular markers, especially mutations in spliceosome genes, are increasingly important for MDS diagnosis and prognosis.

Conclusions:

• MDS diagnosis integrates morphology, cytogenetics, and advanced molecular techniques.
• Prognostication is refined by incorporating cytogenetic and molecular findings.
• Future MDS management will likely involve targeted therapies based on identified gene mutations, such as those in the spliceosome.